Gene therapy for cystic fibrosis in humans by liposome-mediated DNA transfer: the production of resources and the regulatory process.
The number of clinical trials using gene transfer technology, either active or under discussion, is increasing rapidly. However, little information is available describing the regulatory procedures or safety specifications that must be considered before initiation of such trials in Europe. We describe the procedure used by our group to produce resources for the first stage of a phase I trial of liposome-mediated gene therapy for cystic fibrosis. The current lack of written and co-ordinated guidance from the numerous interested regulatory agencies within the UK and Europe makes determination of the appropriate safety specifications and procedures for these novel trials difficult, as does the fact that some new agencies (such as the Genetic Therapy Advisory Committee in the UK) and some which are unfamiliar with clinical trials (such as the Department of the Environment) are involved as well as the Medicines Control Agency. In addition, we estimate that the realistic cost of these trials, which in many cases will have to be covered from research budgets provided by government agencies or medical charities, could lead to delays in the clinical application of this important new therapeutic strategy.
Caplen
N J
NJ
Department of Biochemistry and Molecular Genetics, St Mary's Hospital Medical School, London, UK.
Gao
X
X
Hayes
P
P
Elaswarapu
R
R
Fisher
G
G
Kinrade
E
E
Chakera
A
A
Schorr
J
J
Hughes
B
B
Dorin
J R
JR
D001483:Base Sequence; D002985:Clinical Protocols; D017321:Clinical Trials, Phase I as Topic / Q000191:economics / Q000331:legislation & jurisprudence / Q000592:standards; D003550:Cystic Fibrosis / Q000628:therapy*; D019005:Cystic Fibrosis Transmembrane Conductance Regulator / Q000235:genetics; D017931:DNA Primers / Q000235:genetics; D004274:DNA, Recombinant / Q000008:administration & dosage / Q000235:genetics / Q000627:therapeutic use*; D004992:Ethics, Medical; D018014:Gene Transfer Techniques; D015316:Genetic Therapy; D006801:Humans; D008081:Liposomes; D008969:Molecular Sequence Data; D011786:Quality Control; D012449:Safety; D006113:United Kingdom
C505032:CFTR protein, human; D017931:DNA Primers; D004274:DNA, Recombinant; D008081:Liposomes; D019005:Cystic Fibrosis Transmembrane Conductance Regulator